Trial Profile
A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs ABY 029 (Primary)
- Indications Head and neck cancer
- Focus Diagnostic use
- 26 Apr 2021 Status changed from active, no longer recruiting to completed.
- 18 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 19 Nov 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.